5-HTP and Creatine for Depression R33 Phase

NCT ID: NCT05895747

Last Updated: 2025-08-08

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 106 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-09-28
• Study Completion Date: 2026-07-31

Brief Summary

This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma serotonin levels.

Detailed Description

Major depressive disorder (MDD) has a lifetime prevalence of over 16% and is associated with reduced work productivity, disability, increased mortality, and increased rates of suicide attempts and completed suicides. Unfortunately, ~34% fail to respond to standard ADs (ADs). Environmental and patient-level factors that increase the risk of MDD could pinpoint novel mechanisms underlying the disorder. One such factor may be relative hypoxia. Persons with hypoxic medical conditions, such as asthma and chronic obstructive pulmonary disease, are at higher risk of depression and suicide compared to those with other chronic medical conditions. Smoking also promotes hypoxia and is linked to increased risks of suicide and depression. Of special relevance to this study, living at high altitude produces relative hypoxia even after months, and is linked to increased risks of suicide and depression. Hypoxia could contribute to MDD in at least two ways. First, brain bioenergetics are altered in both hypoxia and MDD. Hypoxia reduces several neurochemical markers of brain activity, including phosphocreatine (PCr) and n-acetylaspartate (NAA), and alters mitochondrial dynamics in the hippocampus. Proton magnetic resonance spectroscopy (1H-MRS) shows that high-altitude residents have altered whole brain pH and reduced inorganic phosphate to total phosphate (tP) ratios compared to persons dwelling at sea-level. In depressed patients, phosphorus MRS (31P-MRS) shows reduced nucleotide triphosphate (NTP) concentrations and decreased PCr concentrations; AD response is associated with increases in PCr and NTP. Hypoxia could also promote MDD by altering serotonin (5-HT) production. Chronic hypoxia reduces 5-HT in the forebrain and brainstem in rodents. The conversion of tryptophan to 5-hydroxytryptophan (5-HTP) by tryptophan hydroxylase is oxygen-dependent and slowed by hypoxia. Animal studies have shown that selective serotonin reuptake inhibitors (SSRIs) are not as effective at altitude, possibly because of inadequate 5-HT production. Reductions in 5-HT synthesis and inefficiencies in bioenergetics could both contribute to altered brain functional connectivity. MDD may disrupt cortical emotion regulation, and resting state functional connectivity (fcMRI) studies suggest that depression involves reduced connectivity between frontal cortical regions and the amygdala, while AD response correlates with normalization of those connections. Alterations in connectivity associated with AD response are correlated with changes in brain metabolites, suggesting a link to brain bioenergetics.

This suggests two natural supplements as interventions for depression. Oral creatine monohydrate (Cr) could improve bioenergetics in MDD, as Cr alters brain tCr, PCr, and NTP levels. Moreover, Cr produces improvements in mood correlated with normalization of PCr levels and structural connectivity. Alterations in 5-HT synthesis due to hypoxia could be rectified by 5-HTP, as its conversion to 5-HT is not oxygen-dependent. 5-HTP elevates brain 5-HT levels and has AD efficacy in clinical trials. The proposed study is a two-phase, three-armed trial to evaluate whether SSRI/SNRI augmentation with the supplements Cr, 5-HTP, or their combination (5-HTP+Cr) can enhance AD response in treatment-resistant MDD. In the R61 phase, the study will assess the ability of the interventions to alter biological signatures associated with depression, as measured by 31P-MRS, fcMRI, and changes in whole blood 5-HT. In the R33 phase, the study will attempt to replicate the above findings with dose variation and evaluate their correlation with clinical outcomes. The study will have the following aims:

Aim 1. Replicate the clinically meaningful changes in biological signatures (PCr:tP ratios as measured by 31P-MRS, sgACC connectivity as measured by fcMRI, and whole blood serotonin) demonstrated in the R61 phase, following the decision rule noted above.

Aim 2. Demonstrate that the changes in each of the above markers that is carried over from the R61 phase are correlated with changes in depression as measured by the 17-item Hamilton Depression Rating Scale, which would be studied in a subsequent efficacy trial.

Study results will help elucidate the potential efficacy of a novel combination of nutritional supplements in persons with MDD, given strong epidemiologic and physiologic evidence suggesting that relative hypoxia can contribute to depression through alterations in brain bioenergetics and 5-HT synthesis. Target engagement will be indicated by improvements in functional connectivity and frontal cortical energy metabolism.

Conditions

Major Depressive Disorder

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Low Dose 5-hydroxytryptophan and Creatine Monohydrate

5-HTP 100mg PO BID plus creatine 5g PO Qday

Group Type: EXPERIMENTAL

Low Dose 5-hydroxytryptophan

Intervention Type: DRUG

5-hydroxytryptophan 100mg PO BID

Low Dose Creatine Monohydrate

Intervention Type: DRUG

Creatine monohydrate 5g PO qday

Placebo

Intervention Type: DRUG

Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)

High Dose 5-hydroxytryptophan and Creatine Monohydrate

5-HTP 200mg PO BID plus creatine 10mg PO Qday

Group Type: EXPERIMENTAL

High Dose 5-hydroxytryptophan

Intervention Type: DRUG

5-hydroxytryptophan 200mg PO BID

High Dose Creatine Monohydrate

Intervention Type: DRUG

Creatine monohydrate 10g PO qday

Double Placebo

Creatine-matched placebo and 5-HTP-matched placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)

Interventions

Low Dose 5-hydroxytryptophan

5-hydroxytryptophan 100mg PO BID

Intervention Type: DRUG

High Dose 5-hydroxytryptophan

5-hydroxytryptophan 200mg PO BID

Intervention Type: DRUG

Low Dose Creatine Monohydrate

Creatine monohydrate 5g PO qday

Intervention Type: DRUG

High Dose Creatine Monohydrate

Creatine monohydrate 10g PO qday

Intervention Type: DRUG

Placebo

Creatine-matched placebo and 5-HTP-matched placebo; Placebo will be dextrose either encapsulated (5-HTP matched) or as loose powder (creatine matched)

Intervention Type: DRUG

Other Intervention Names

5-HTP; 5-HTP; creatine; creatine; dextrose

Eligibility Criteria

Inclusion Criteria

• Adults age 18-65 years inclusive
• Current diagnosis of MDD identified by the MINI (Mini Neuropsychiatric Interview)
• Current HAM-D17 score of >= 16
• Adequate adherence to any FDA approved SSRI or SNRI for at least 8 weeks
• Right-handed
• Residing at > 4000 ft for at least 12 weeks

Exclusion Criteria

• Any non-MDD and non-anxiety psychiatric diagnosis, as identified by the MINI
• History of or current diagnosis of renal disease, such as chronic renal failure, acute renal failure or end stage renal disease
• Current colitis or diverticulitis
• History of or current pulmonary disease (except well controlled asthma)
• Current smoking
• History of cardiac disease or QTc > 500ms
• History of fibromyalgia or any rheumatological condition
• History of or current seizure disorder
• Current serious suicide risk identified by the Columbia Severity Suicide Rating Scale
• Current treatment with an antipsychotic, mood stabilizer, or non-SSRI/SNRI antidepressant except for bupropion at FDA-approved doses or trazodone up to 200mg, or use of any supplements apart from standard multivitamins
• Positive pregnancy test, pregnancy, failure to use adequate birth control method
• Previous diagnosis of serotonin syndrome or evidence of serotonin syndrome
• Pre-existing eosinophilia (absolute eosinophil count > 500/uL)
• Contraindications to MRI: ferromagnetic implants, implanted devices, claustrophobia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Utah

OTHER

Sponsor Role: lead

Responsible Party

Brent Michael Kious, MD, PhD

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University of Utah Department of Psychiatry

Salt Lake City, Utah, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Brent Kious, MD

Role: CONTACT

brent.kious@hsc.utah.edu

8015851418

Hailey Nielson, MS

Role: CONTACT

hailey.nielson@utah.edu

801-581-3475

Facility Contacts

Brent Kious

Role: primary

brent.kious@hsc.utah.edu

8015851418

Other Identifiers

IRB_00132830_R33

Identifier Type: -

Identifier Source: org_study_id